618 related articles for article (PubMed ID: 23028132)
1. Neurovascular dysfunction and faulty amyloid β-peptide clearance in Alzheimer disease.
Sagare AP; Bell RD; Zlokovic BV
Cold Spring Harb Perspect Med; 2012 Oct; 2(10):. PubMed ID: 23028132
[TBL] [Abstract][Full Text] [Related]
2. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease.
Bell RD; Zlokovic BV
Acta Neuropathol; 2009 Jul; 118(1):103-13. PubMed ID: 19319544
[TBL] [Abstract][Full Text] [Related]
3. Neurovascular defects and faulty amyloid-β vascular clearance in Alzheimer's disease.
Sagare AP; Bell RD; Zlokovic BV
J Alzheimers Dis; 2013; 33 Suppl 1(0 1):S87-100. PubMed ID: 22751174
[TBL] [Abstract][Full Text] [Related]
4. Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease.
Deane R; Zlokovic BV
Curr Alzheimer Res; 2007 Apr; 4(2):191-7. PubMed ID: 17430246
[TBL] [Abstract][Full Text] [Related]
5. New therapeutic targets in the neurovascular pathway in Alzheimer's disease.
Zlokovic BV
Neurotherapeutics; 2008 Jul; 5(3):409-14. PubMed ID: 18625452
[TBL] [Abstract][Full Text] [Related]
6. Neurovascular mechanisms of Alzheimer's neurodegeneration.
Zlokovic BV
Trends Neurosci; 2005 Apr; 28(4):202-8. PubMed ID: 15808355
[TBL] [Abstract][Full Text] [Related]
7. RAGE (yin) versus LRP (yang) balance regulates alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier.
Deane R; Wu Z; Zlokovic BV
Stroke; 2004 Nov; 35(11 Suppl 1):2628-31. PubMed ID: 15459432
[TBL] [Abstract][Full Text] [Related]
8. Alzheimer's Disease: The Link Between Amyloid-β and Neurovascular Dysfunction.
Solis E; Hascup KN; Hascup ER
J Alzheimers Dis; 2020; 76(4):1179-1198. PubMed ID: 32597813
[TBL] [Abstract][Full Text] [Related]
9. Mild chronic cerebral hypoperfusion induces neurovascular dysfunction, triggering peripheral beta-amyloid brain entry and aggregation.
ElAli A; Thériault P; Préfontaine P; Rivest S
Acta Neuropathol Commun; 2013 Nov; 1():75. PubMed ID: 24252187
[TBL] [Abstract][Full Text] [Related]
10. ADAMTS13 maintains cerebrovascular integrity to ameliorate Alzheimer-like pathology.
Cao Y; Xu H; Zhu Y; Shi MJ; Wei L; Zhang J; Cheng S; Shi Y; Tong H; Kang L; Lu L; Luo H; Yang X; Bai X; Wang R; Ma Y; Wang Y; Wang Z; Zhong K; Zhao BQ; Fan W
PLoS Biol; 2019 Jun; 17(6):e3000313. PubMed ID: 31185010
[TBL] [Abstract][Full Text] [Related]
11. Hypertension induces brain β-amyloid accumulation, cognitive impairment, and memory deterioration through activation of receptor for advanced glycation end products in brain vasculature.
Carnevale D; Mascio G; D'Andrea I; Fardella V; Bell RD; Branchi I; Pallante F; Zlokovic B; Yan SS; Lembo G
Hypertension; 2012 Jul; 60(1):188-97. PubMed ID: 22615109
[TBL] [Abstract][Full Text] [Related]
12. Differences in amyloid-β clearance across mouse and human blood-brain barrier models: kinetic analysis and mechanistic modeling.
Qosa H; Abuasal BS; Romero IA; Weksler B; Couraud PO; Keller JN; Kaddoumi A
Neuropharmacology; 2014 Apr; 79():668-78. PubMed ID: 24467845
[TBL] [Abstract][Full Text] [Related]
13. GLUT1 reductions exacerbate Alzheimer's disease vasculo-neuronal dysfunction and degeneration.
Winkler EA; Nishida Y; Sagare AP; Rege SV; Bell RD; Perlmutter D; Sengillo JD; Hillman S; Kong P; Nelson AR; Sullivan JS; Zhao Z; Meiselman HJ; Wendy RB; Soto J; Abel ED; Makshanoff J; Zuniga E; De Vivo DC; Zlokovic BV
Nat Neurosci; 2015 Apr; 18(4):521-530. PubMed ID: 25730668
[TBL] [Abstract][Full Text] [Related]
14. The blood brain barrier in Alzheimer's disease.
Chakraborty A; de Wit NM; van der Flier WM; de Vries HE
Vascul Pharmacol; 2017 Feb; 89():12-18. PubMed ID: 27894893
[TBL] [Abstract][Full Text] [Related]
15. β-Amyloid, cholinergic transmission, and cerebrovascular system -- a developmental study in a mouse model of Alzheimer's disease.
Kuznetsova E; Schliebs R
Curr Pharm Des; 2013; 19(38):6749-65. PubMed ID: 23530514
[TBL] [Abstract][Full Text] [Related]
16. Aβ₁₋₄₂-RAGE interaction disrupts tight junctions of the blood-brain barrier via Ca²⁺-calcineurin signaling.
Kook SY; Hong HS; Moon M; Ha CM; Chang S; Mook-Jung I
J Neurosci; 2012 Jun; 32(26):8845-54. PubMed ID: 22745485
[TBL] [Abstract][Full Text] [Related]
17. Blood-Brain Barrier Dysfunction and the Pathogenesis of Alzheimer's Disease.
Yamazaki Y; Kanekiyo T
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28902142
[TBL] [Abstract][Full Text] [Related]
18. Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease.
Deane R; Bell RD; Sagare A; Zlokovic BV
CNS Neurol Disord Drug Targets; 2009 Mar; 8(1):16-30. PubMed ID: 19275634
[TBL] [Abstract][Full Text] [Related]
19. Neurovascular dysfunction and neurodegeneration in dementia and Alzheimer's disease.
Nelson AR; Sweeney MD; Sagare AP; Zlokovic BV
Biochim Biophys Acta; 2016 May; 1862(5):887-900. PubMed ID: 26705676
[TBL] [Abstract][Full Text] [Related]
20. Testing the neurovascular hypothesis of Alzheimer's disease: LRP-1 antisense reduces blood-brain barrier clearance, increases brain levels of amyloid-beta protein, and impairs cognition.
Jaeger LB; Dohgu S; Hwang MC; Farr SA; Murphy MP; Fleegal-DeMotta MA; Lynch JL; Robinson SM; Niehoff ML; Johnson SN; Kumar VB; Banks WA
J Alzheimers Dis; 2009; 17(3):553-70. PubMed ID: 19433890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
